HIV LRA/LPA cellular screening platform

HIV LRA/LPA cellular screening platform 

A SupT1 cell luciferase reporter screening platform has been set-up allowing for the identification of LPA (latency promoting agent) or LRA (latency reactivating agent) activity if reporter activity is reduced or increased respectively. An LPA that reduces luciferase activity blocks HIV-1 gene expression (blocking activity). In a second format infected but silenced cells are treated with compound and additionally reactivated with TNFalpha to test the effect of the experimental drugs on reactivation. An LPA that reduces reactivation has locking activity. 

What will you obtain:

Quantitative data on LRA or LPA potency of compounds 

Quantitative data on blocking and locking activity of HIV transcription

Who can benefit it: 

The screening platform is suited to identify LPA/LRAs. Throughput allows prioritization of compounds and therefore the platform is amenable to both early and advanced drug discovery projects. Secondary assays for biological profiling are available at the Debyser lab.  

Unique selling points: 

  1. Identification of LPA and LRA potency 
  2. Full screening pipeline including biological profiling set-up 

Type of collaboration possible: 

​​​☒​​ 

Fee for service 

​​☒​ 

Research collaboration / bilateral contracts / O&O initiatives …  

​​☒​ 

Visiting researcher 

​​☒​ 

VLAIO Baekeland mandate 

​​☒​ 

Space for new IP co-development on novel LRA/LPA 

 

Contact:

  1. Frauke Christ, frauke.christ@kuleuven.be, +32 490 651067, – MAIN CONTACT POINT 
  1. Zeger Debyser, zeger.debyser@kuleuven.be, +32 16 37 40 29 
  1. https://gbiomed.kuleuven.be/english/research/50000715/50488973/molmed/Molecular-Virology-and-Drug-Discovery 

Publications:

1. Debyser Z, Vansant G, Bruggemans A, Janssens J, Christ F. Insight in HIV Integration Site Selection Provides a Block-and-Lock Strategy for a Functional Cure of HIV Infection. Viruses. 2018 Dec 26;11(1):12. doi: 10.3390/v11010012. PMID: 30587760; PMCID: PMC6356730. 

2. Janssens J, Bruggemans A, Christ F, Debyser Z. Towards a Functional Cure of HIV-1: Insight Into the Chromatin Landscape of the Provirus. Front Microbiol. 2021 Mar 18;12:636642. doi: 10.3389/fmicb.2021.636642. PMID: 33868195; PMCID: PMC8044952. 

3. Vansant G, Bruggemans A, Janssens J, Debyser Z. Block-And-Lock Strategies to Cure HIV Infection. Viruses. 2020 Jan 10;12(1):84. doi: 10.3390/v12010084. PMID: 31936859; PMCID: PMC7019976. 

4. Vansant G, Chen HC, Zorita E, Trejbalová K, Miklík D, Filion G, Debyser Z. The chromatin landscape at the HIV-1 provirus integration site determines viral expression. Nucleic Acids Res. 2020 Aug 20;48(14):7801-7817. doi: 10.1093/nar/gkaa536. PMID: 32597987; PMCID: PMC7641320. 

5. Vranckx LS, Demeulemeester J, Saleh S, Boll A, Vansant G, Schrijvers R, Weydert C, Battivelli E, Verdin E, Cereseto A, Christ F, Gijsbers R, Debyser Z. LEDGIN-mediated Inhibition of Integrase-LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV. EBioMedicine. 2016 Jun;8:248-264. doi: 10.1016/j.ebiom.2016.04.039. Epub 2016 May 13. PMID: 27428435; PMCID: PMC4919729. 

WERELDWIJD LEVEN 37 MILJOEN MENSEN MET HIV. STEUN HET FONDS HIV ONTRAFELEN en Help hen.

Ik doe een online gift

Contact HIV Cure

Contact fondsenwerving Ugent (Wim Vanderplanken)

Facebook-f Youtube Instagram